Evidence map›Paper›PMID 29272161›Full record

ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018

Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?

Paul D Brown, Manmeet S Ahluwalia, Osaama H Khan, Anthony L Asher, Jeffrey S Wefel, Vinai Gondi

Abstract readReview
In one paragraph

Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 6 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 6 syntheses or guidelines pooled it, 232 citations in OpenAlex.

  1. Pooled it
  2. Efficacy and safety of stereotactic radiosurgery versus whole brain radiotherapy for the treatment of brain metastasis: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Evidence-based guidelines for hypofractionated radiation in breast cancer: conclusions of the Catalan expert working group.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Pooled it
  6. Health-related quality of life in adult patients with brain metastases after stereotactic radiosurgery: a systematic, narrative review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Pooled it
  7. Trial
  8. Effect of Whole-Brain and Intensity-Modulated Radiotherapy on Serum Levels of miR-21 and Prognosis for Lung Cancer Metastatic to the Brain.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Trial
  9. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  10. Trial
  11. Observational
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Paul D BrownPaul D. Brown, Mayo Clinic, Rochester, MN; Manmeet S. Ahluwalia, Cleveland Clinic, Cleveland, OH; Osaama H. Khan and Vinai Gondi, Northwestern University Feinberg School of Medicine, Chicago; Vinai Gondi, Northwestern Medicine Cancer Center, Warrenville, IL; Anthony L. Asher, Carolina Neurosurgery and Spine Associates and Neurosciences Institute, Carolinas HealthCare System, Charlotte, NC; and Jeffrey S. Wefel, University of Texas MD Anderson Cancer Center, Houston, TX.
Manmeet S AhluwaliaPaul D. Brown, Mayo Clinic, Rochester, MN; Manmeet S. Ahluwalia, Cleveland Clinic, Cleveland, OH; Osaama H. Khan and Vinai Gondi, Northwestern University Feinberg School of Medicine, Chicago; Vinai Gondi, Northwestern Medicine Cancer Center, Warrenville, IL; Anthony L. Asher, Carolina Neurosurgery and Spine Associates and Neurosciences Institute, Carolinas HealthCare System, Charlotte, NC; and Jeffrey S. Wefel, University of Texas MD Anderson Cancer Center, Houston, TX.
Osaama H KhanPaul D. Brown, Mayo Clinic, Rochester, MN; Manmeet S. Ahluwalia, Cleveland Clinic, Cleveland, OH; Osaama H. Khan and Vinai Gondi, Northwestern University Feinberg School of Medicine, Chicago; Vinai Gondi, Northwestern Medicine Cancer Center, Warrenville, IL; Anthony L. Asher, Carolina Neurosurgery and Spine Associates and Neurosciences Institute, Carolinas HealthCare System, Charlotte, NC; and Jeffrey S. Wefel, University of Texas MD Anderson Cancer Center, Houston, TX.
Anthony L AsherPaul D. Brown, Mayo Clinic, Rochester, MN; Manmeet S. Ahluwalia, Cleveland Clinic, Cleveland, OH; Osaama H. Khan and Vinai Gondi, Northwestern University Feinberg School of Medicine, Chicago; Vinai Gondi, Northwestern Medicine Cancer Center, Warrenville, IL; Anthony L. Asher, Carolina Neurosurgery and Spine Associates and Neurosciences Institute, Carolinas HealthCare System, Charlotte, NC; and Jeffrey S. Wefel, University of Texas MD Anderson Cancer Center, Houston, TX.
Jeffrey S WefelPaul D. Brown, Mayo Clinic, Rochester, MN; Manmeet S. Ahluwalia, Cleveland Clinic, Cleveland, OH; Osaama H. Khan and Vinai Gondi, Northwestern University Feinberg School of Medicine, Chicago; Vinai Gondi, Northwestern Medicine Cancer Center, Warrenville, IL; Anthony L. Asher, Carolina Neurosurgery and Spine Associates and Neurosciences Institute, Carolinas HealthCare System, Charlotte, NC; and Jeffrey S. Wefel, University of Texas MD Anderson Cancer Center, Houston, TX.
Vinai GondiPaul D. Brown, Mayo Clinic, Rochester, MN; Manmeet S. Ahluwalia, Cleveland Clinic, Cleveland, OH; Osaama H. Khan and Vinai Gondi, Northwestern University Feinberg School of Medicine, Chicago; Vinai Gondi, Northwestern Medicine Cancer Center, Warrenville, IL; Anthony L. Asher, Carolina Neurosurgery and Spine Associates and Neurosciences Institute, Carolinas HealthCare System, Charlotte, NC; and Jeffrey S. Wefel, University of Texas MD Anderson Cancer Center, Houston, TX.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

An estimated 20% of patients with cancer will develop brain metastases. Approximately 200,000 individuals in the United States alone receive whole-brain radiotherapy (WBRT) each year to treat brain metastases. Historically, the prognosis of patients with brain metastases has been poor; however, with new therapies, this is changing. Because patients are living longer following the diagnosis and treatment of brain metastases, there has been rising concern about treatment-related toxicities associated with WBRT, including neurocognitive toxicity. In addition, recent clinical trials have raised questions about the use of WBRT. To better understand this rapidly changing landscape, this review outlines the treatment roles and toxicities of WBRT and alternative therapies for the management of brain metastases.

Indexed as

Antineoplastic AgentsBrain NeoplasmsCombined Modality TherapyCranial IrradiationElectric Stimulation TherapyHumansMetastasectomyPalliative CareRadiosurgeryRadiotherapy, AdjuvantSalvage TherapyAntineoplastic Agents

Identifiers

PMID29272161
PMCPMC6075843
OpenAlexW2779252711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.